Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) | |
US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) |
Aplenzin is owned by Bausch.
Aplenzin contains Bupropion Hydrobromide.
Aplenzin has a total of 8 drug patents out of which 0 drug patents have expired.
Aplenzin was authorised for market use on 23 April, 2008.
Aplenzin is available in tablet, extended release;oral dosage forms.
Aplenzin can be used as treatment of major depressive disorder by dosing at intervals of 24 hours.
The generics of Aplenzin are possible to be released after 27 June, 2026.
Drugs and Companies using BUPROPION HYDROBROMIDE ingredient
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE;ORAL